Repatha 140 mg Solution for subcutaneous injection
PDF Leaflet Revision Date: 23 June 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct treatment for hypercholesterolaemia and mixed dyslipidaemia.
Dosage (summary)
140 mg every 2 weeks or 420 mg once monthly for adults and children 10 years and older.
Onset of Action / Duration
Onset: 4 hours, Duration: 14-21 days.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use only if necessary during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Statins (increased clearance of evolocumab)
Contraindications
- Hypersensitivity to evolocumab or excipients
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Back pain
- Arthralgia
- Injection site reactions
Counselling Points
- Rotate injection sites
- Monitor for allergic reactions
- Report any unusual symptoms
Serious warnings
- Caution in moderate to severe hepatic impairment
- Risk of allergic reactions due to latex
Important Disclaimer
The Repatha 140 mg Solution for subcutaneous injection professional information leaflet below is the property of Amgen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
